EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contrasting Impacts of Targeted Disruption of the Cancer Stem Cell Marker CD133 and Its Epigenetic Regulator TRIM28 in Colorectal Cancer Cells

Irina V Kholodenko iD, Aleena A Saidova, Daria M Potashnikova, Viktoriia A Arzumanian iD, Daniil D Romashin iD, Anna V Tvorogova, Ekaterina V Poverennaya iD, Konstantin N Yarygin iD, Yan S Kim iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Irina V Kholodenko und 8 weiteren Autor:innen. Beteiligte Einrichtung: V.N. Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia. Hauptthemen laut MEDLINE: AC133 Antigen, Colorectal Neoplasms, Neoplastic Stem Cells, Tripartite Motif-Containing Protein 28. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer stem cells (CSCs) play a crucial role in colorectal cancer by sustaining intratumoral heterogeneity, therapeutic resistance, and metastatic potential. CD133 (PROM1) is among the most frequently used surface markers for CSC identification, whereas TRIM28, a versatile epigenetic regulator, has been implicated in controlling CD133 expression and stem-like features. In this study, we performed a detailed molecular and functional analysis of Caco2 colorectal cancer cell clones with individual knockouts of CD133 or TRIM28. Elimination of CD133 neither altered global gene expression, as confirmed by transcriptome profiling, nor affected key cellular properties. In contrast, loss of TRIM28 led to a marked reduction in CD133 protein abundance and induced extensive molecular and phenotypic remodeling. TRIM28 knockout was associated with broad transcriptomic changes involving more than 500 differentially expressed genes, decreased proliferative activity monitored by time-lapse imaging, and reduced sensitivity to paclitaxel, cisplatin, and curcumin. Furthermore, immune evasion molecules CD24 and CD47 (“don’t eat me” signals) were strongly upregulated in TRIM28-deficient cells, consistently confirmed by both RNA-Seq and flow cytometry analyses. At the same time, imaging flow cytometry and mitochondrial activity assays indicated that these effects were not due to major shifts in mitotic index or bioenergetic status. Altogether, our results demonstrate that TRIM28, rather than CD133, functions as a central regulator of CSC-associated phenotypes in colorectal cancer. These findings highlight the importance of epigenetic context in CSC biology and may inform the development of more effective therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AC133 AntigenColorectal NeoplasmsNeoplastic Stem CellsTripartite Motif-Containing Protein 28Epigenesis, GeneticHumansGene Expression Regulation, NeoplasticCaco-2 CellsBiomarkers, TumorCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

CD133TRIM28cancer heterogeneitycancer stem cells

Substanzen

AC133 AntigenTripartite Motif-Containing Protein 28PROM1 protein, humanTRIM28 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • V.N. Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.
  • Biology Department, Shenzhen MSU-BIT University, Shenzhen 517182, China.
  • Department of Cell Biology and Histology, School of Biology, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.
  • Center of Genomic Sciences, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.

ORCID-Profile: Irina V Kholodenko, Viktoriia A Arzumanian, Daniil D Romashin, Ekaterina V Poverennaya, Konstantin N Yarygin, Yan S Kim

Förderung

  • Russian Science Foundation

Zitieren

APA

Kholodenko, I. V., Saidova, A. A., Potashnikova, D. M., Arzumanian, V. A., Romashin, D. D., Tvorogova, A. V., Poverennaya, E. V., Yarygin, K. N., & Kim, Y. S. (2025). Contrasting Impacts of Targeted Disruption of the Cancer Stem Cell Marker CD133 and Its Epigenetic Regulator TRIM28 in Colorectal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210862

Vancouver

Kholodenko IV, Saidova AA, Potashnikova DM, Arzumanian VA, Romashin DD, Tvorogova AV, et al. Contrasting Impacts of Targeted Disruption of the Cancer Stem Cell Marker CD133 and Its Epigenetic Regulator TRIM28 in Colorectal Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210862

BibTeX
@article{Kholodenko2025,
  author = {Kholodenko, Irina V and Saidova, Aleena A and Potashnikova, Daria M and Arzumanian, Viktoriia A and Romashin, Daniil D and Tvorogova, Anna V and Poverennaya, Ekaterina V and Yarygin, Konstantin N and Kim, Yan S},
  title = {Contrasting Impacts of Targeted Disruption of the Cancer Stem Cell Marker CD133 and Its Epigenetic Regulator TRIM28 in Colorectal Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210862}
}
Kostenlos starten →